The Billion-Dollar Blockade: How to Dismantle Drug Patent Thickets and Reclaim the Market
The pharmaceutical landscape in the United States is currently defined by a paradox: a system designed to foster innovation has […]
The 180-Day Prize: Using Orange Book Patent Data to Secure Early Market Control
Economic success in the generic pharmaceutical industry depends on timing. Between 2026 and 2030, blockbuster drugs representing an estimated $236
The 180-Day Prize: Using Orange Book Patent Data to Secure Early Market Control Read Post »
The Math of Monopoly: Why a 20-Year Drug Patent Lasts Only 12 Years
The 20-year patent term is a nominal legal baseline that rarely reflects the commercial reality of a pharmaceutical product. While
The Math of Monopoly: Why a 20-Year Drug Patent Lasts Only 12 Years Read Post »
Know Before the Cliff: How to Forecast Drug Patent Expiry
The Billion-Dollar Blind Spot in Pharmaceutical Strategy Every year, pharmaceutical executives sit in board meetings with revenue projections that quietly
Know Before the Cliff: How to Forecast Drug Patent Expiry Read Post »
Top Paragraph IV Litigation Trends and What They Mean for Pharma
Every major drug facing generic competition is a battlefield. The weapon of choice is not chemistry or clinical data—it is
Top Paragraph IV Litigation Trends and What They Mean for Pharma Read Post »
Off-Patent Drugs, On Profit: How Branded Generics Earn 20%+ Margins
Branded generics occupy a middle ground between expensive branded drugs and bare-bones unbranded generics. These products use off-patent active ingredients
Off-Patent Drugs, On Profit: How Branded Generics Earn 20%+ Margins Read Post »
The Trust Proxy: How To Charge 100% More For The Same Pill
The pharmaceutical industry has long been viewed through a binary lens. On one side, the high-stakes, high-margin world of patented
The Trust Proxy: How To Charge 100% More For The Same Pill Read Post »
The Margin Machine: How Branded Generics Print 20%+ Returns on Drugs Anyone Can Make
An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in
The Margin Machine: How Branded Generics Print 20%+ Returns on Drugs Anyone Can Make Read Post »
How to fix the $2.6 billion drug discovery problem
The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a
How to fix the $2.6 billion drug discovery problem Read Post »
